Clinical usefulness of CEA, CA19-9, and CYFRA 21-1 as tumor markers for urothelial bladder carcinoma

Urologia Internationalis

Volumn 87, Issue 4, 2011, Pages 420-428

  Washino, Satoshi ^a   Hirai, Masaru ^a   Matsuzaki, Atsushi ^a   Kobayashi, Yutaka ^a  

^a Saitama Medical University   (Japan)

Author keywords

Bladder cancer; CA19 9; CEA; CYFRA 21 1; Tumor marker; Urothelial carcinoma

Indexed keywords

CA19 9; CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 19 FRAGMENT; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER GRADING; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; FEMALE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TRANSITIONAL CELL CARCINOMA;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CARCINOMA; CARCINOMA, SQUAMOUS CELL; CHI-SQUARE DISTRIBUTION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; JAPAN; KAPLAN-MEIER ESTIMATE; KERATIN-19; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 84355166581     PISSN: 00421138     EISSN: 14230399     Source Type: Journal    
DOI: 10.1159/000327517     Document Type: Article

References (11)

1. Stenzl A, Cowan NC, De Santis M, Jakse G, Kuczyk MA, Merseburger AS, Ribal MJ, Sherif A, Witjes JA: The updated EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol 2009; 55: 815-825.
2. Catto JW, Abbod MF, Wild PJ, Linkens DA, Pilarsky C, Rehman I, Rosario DJ, Denzinger S, Burger M, Stoehr R, Knuechel R, Hartmann A, Hamdy FC: The application of artificial intelligence to microarray data: Identification of a novel gene signature to identify bladder cancer progression. Eur Urol 2010; 57: 398-406.
3. Goossens-Laan CA, Kil PJ, Roukema JA, Bosch JL, De Vries J: Quality of care indicators for muscle-invasive bladder cancer. Urol Int 2011; 86: 11-18.
4. Katkoori D, Manoharan M, Araki M, Soloway MS: Role of patient-physician dialogue in selecting the type of urinary diversion. Urol Int 2010; 84: 40-44.
5. Villavicencio H, Rodriguez Faba O, Palou J, Gausa L, Algaba F, Marcuello E: Bladder preservation strategy based on combined therapy in patients with muscle-invasive bladder cancer: Management and results at long-term follow-up. Urol Int 2010; 85: 281-286.
6. Yencilek F, Onal B, Erozenci A, Talat Z, Ataus S: Intermediate-risk group in patients with transitional cell carcinoma of the bladder: Prediction of high-risk patients in this heterogeneous group. Urol Int 2009; 83: 295-299.
7. Song YS, Cho JS, Cho KS, Doo SH, Chung BH, Kim SJ, Yang WJ, Song KH, Kim CI, Hong SJ: Efficacy of adjuvant gemcitabine-cisplatin chemotherapy: A comparative study between locally advanced transitional cell carcinoma of the bladder and upper urinary tract. Urol Int 2010; 85: 47-51.
8. van Rhijn BW, Burger M, Lotan Y, Solsona E, Stief CG, Sylvester RJ, Witjes JA, Zlotta AR: Recurrence and progression of disease in nonmuscle- invasive bladder cancer: From epidemiology to treatment strategy. Eur Urol 2009; 56: 430-442.
9. Zaak D, Burger M, Otto W, Bastian PJ, Denzinger S, Stief CG, Buchner H, Hartmann A, Wieland WF, Shariat SF, Fritsche HM: Predicting individual outcomes after radical cystectomy: An external validation of current nomograms. BJU Int 2010; 106: 342-348.
10. Nisman B, Yutkin V, Peretz T, Shapiro A, Barak V, Pode D: The followup of patients with non-muscle-invasive bladder cancer by urine cytology, abdominal ultrasound and urine CYFRA 21-1: A pilot study. Anticancer Res 2009; 29: 4281-4285.
11. Suyama T, Nakajima K, Kanbe S, Tanaka N, Hara H, Ishii N: Prognostic significance of preoperative serum CYFRA 21-1 in patients with upper urinary tract urothelial carcinoma. Int J Urol 2011; 18: 43-47.